Spots Global Cancer Trial Database for thyroid gland anaplastic carcinoma

Every month we try and update this database with for thyroid gland anaplastic carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer	NCT04759911	Malignant Thyro... Poorly Differen... Recurrent Thyro... Thyroid Gland A... Thyroid Gland M... Thyroid Gland P... Thyroid Gland S...	Quality-of-Life... Questionnaire A... Selpercatinib Therapeutic Con...	12 Years -	M.D. Anderson Cancer Center
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas	NCT03449108	Bone Sarcoma Dedifferentiate... Giant Cell Tumo... Malignancy in G... Malignant Solid... Ovarian Carcino... Platinum-Resist... Poorly Differen... Recurrent Osteo... Recurrent Ovari... Refractory Oste... Soft Tissue Sar... Thyroid Gland A... Thyroid Gland S... Undifferentiate... Triple Negative...	Aldesleukin Autologous Tumo... Autologous Tumo... Cyclophosphamid... Fludarabine Ipilimumab Nivolumab Quality-of-Life... Questionnaire A...	16 Years - 70 Years	M.D. Anderson Cancer Center
Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer	NCT04739566	Thyroid Gland A...	Dabrafenib Trametinib	18 Years -	Saint Petersburg State University, Russia
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	NCT03975231	BRAF NP_004324.... BRAF V600K Muta... Thyroid Gland A...	Dabrafenib Intensity-Modul... Trametinib	18 Years -	City of Hope Medical Center
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer	NCT03181100	Metastatic Thyr... Poorly Differen... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Thyroid Gland A... Unresectable Th...	Atezolizumab Bevacizumab Cobimetinib Nab-paclitaxel Paclitaxel Vemurafenib	18 Years -	M.D. Anderson Cancer Center
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer	NCT00625846	Recurrent Thyro... Stage III Diffe... Stage III Thyro... Stage IVA Diffe... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Diffe... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Diffe... Stage IVC Thyro... Stage IVC Thyro... Thyroid Gland A...	Laboratory Biom... Pazopanib Hydro...	19 Years -	National Cancer Institute (NCI)
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer	NCT01236547	Thyroid Gland A...	Intensity-Modul... Paclitaxel Pazopanib Hydro... Placebo Adminis...	18 Years -	National Cancer Institute (NCI)
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer	NCT04759911	Malignant Thyro... Poorly Differen... Recurrent Thyro... Thyroid Gland A... Thyroid Gland M... Thyroid Gland P... Thyroid Gland S...	Quality-of-Life... Questionnaire A... Selpercatinib Therapeutic Con...	12 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: